...
首页> 外文期刊>Molecular medicine reports >Effects of cinobufacini injection on cell proliferation and the expression of topoisomerases in human HepG-2 hepatocellular carcinoma cells
【24h】

Effects of cinobufacini injection on cell proliferation and the expression of topoisomerases in human HepG-2 hepatocellular carcinoma cells

机译:cinobufacini注射液对人HepG-2肝癌细胞增殖和拓扑异构酶表达的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

The present study aimed to investigate the effects of cinobufacini injection on the proliferation and expression of topoisomerases in human HepG-2 hepatocarcinoma cells. The cells were divided into a control group and an experimental group, in which 0.105, 0.21, 0.42 mg/l cinobufacini was injected. Cell proliferation was assessed using a 3-(4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide assay, levels of apoptosis were detected using annexin V/propidium iodide staining and cell cycles were analyzed using flow cytometric analysis. The mRNA and protein expression levels of topoisomerase (TOPO) I and TOPO II were determined by reverse transcription-quantitative polymerase chain reaction and western blotting, respectively. Cinobufacini injection significantly inhibited the proliferation of the HepG-2 cells (P<0.05), induced apoptosis (P<0.05) in a dose- and time-dependent manner, induced tumor cell arrest at the S phase in a dose-dependent manner, and downregulated the mRNA and protein expression levels of TOPO I and TOPO II (P<0.05) in a dose-dependent manner. Therefore, cinobufacini was found to inhibit human HepG-2 hepatocellular carcinoma cell proliferation, and downregulation of the expression levels of TOPO I and TOPO II may contribute to the effect on proliferation observed in the Hep-G(2) cells following cinobbufacini injection.
机译:本研究旨在研究cinobufacini注射液对人HepG-2肝癌细胞中拓扑异构酶的增殖和表达的影响。将细胞分为对照组和实验组,分别注射0.105、0.21、0.42 mg / l cinobufacini。使用3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四唑溴化物测定评估细胞增殖,使用膜联蛋白V /碘化丙啶染色检测细胞凋亡水平,并使用流式细胞仪分析细胞周期。拓扑异构酶(TOPO)I和TOPO II的mRNA和蛋白表达水平分别通过逆转录定量聚合酶链反应和蛋白质印迹法确定。 Cinobufacini注射液显着抑制HepG-2细胞的增殖(P <0.05),以剂量和时间依赖性方式诱导凋亡(P <0.05),以剂量依赖性方式诱导S期肿瘤细胞停滞,下调TOPO I和TOPO II的mRNA和蛋白表达水平(P <0.05)。因此,发现cinobufacini抑制人HepG-2肝细胞癌细胞的增殖,并且TOPO I和TOPO II的表达水平下调可能有助于对inobufacini注射后在Hep-G(2)细胞中观察到的增殖的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号